Temozolomide, an oral chemotherapy drug that is frequently used to treat GBM, was delivered for therapeutic effects to GBM stem cells through a liposome conjugated to both angiopep-2, a peptide that transcytoses the BBB through LRP1 binding, and CD133, a biomarker for glioma stem cells (a subset of tumor cells that display high resistance to chemotherapy and radiation therapy) [161]. Here, LRP1 is linked to glioblastoma.